Literature DB >> 15763350

Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C.

Thierry Thevenot1, Claude Bachmeyer, Rabah Hammi, Patrice Dumouchel, Isabelle Ducamp-Posak, Jean-François Cadranel.   

Abstract

Porphyria cutanea tarda (PCT) is a metabolic disorder characterized by a reduced hepatic activity of uroporphynogen decarboxylase (URO-D), an enzyme of the heme synthesis. The clinical features of PCT may be brought into light by hepatic injury induced by hepatitis C virus (HCV). A significant association between HCV and PCT is well recognized, although the role of HCV in the appearance of PCT is still debated because confounding factors often coexist, such as alcohol, other viruses, drugs or iron overload (). HCV therapy may improve PCT although PCT was rarely reported as a de novo occurrence during an interferon/ribavirin therapy (Jessner et al. Hepatology 2002;36:1301-1302); here, we describe two such other cases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15763350     DOI: 10.1016/j.jhep.2004.10.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

Review 1.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094

2.  Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda.

Authors:  Ashwani K Singal; Krishna V R Venkata; Sarat Jampana; Fakhar-Ul Islam; Karl E Anderson
Journal:  Am J Med Sci       Date:  2017-03-08       Impact factor: 2.378

3.  Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.

Authors:  James Azim; Heather McCurdy; Richard-H Moseley
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.